Latest Ionis News & Updates

See the latest news and media coverage for Ionis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Ionis

RNA- and DNA-targeted medicines developer

ionis.com

Headquarters: Carlsbad, United States
Founded year: 1989
Company type: Public company
Number of employees: 500–1,600

Last updated Today

Latest news about Ionis

In short: Ionis Pharmaceuticals reported strong 2026 growth driven by pivotal Phase 3 clinical successes, new drug approvals, and a robust revenue outlook.

Company announcements

June 8 Ionis

Ionis appoints Ludwig Hantson to Board of Directors

Hantson is a former CEO of Alexion with over 30 years of biopharma experience.

June 4 Ionis

Ionis presents new analyses from olezarsen pivotal studies at congresses

The Phase 3 results support the drug for severe hypertriglyceridemia, with FDA decision expected by June 30, 2026.

May 28 Ionis

Ionis announces positive Phase 3 results for hepatitis B treatment

The investigational medicine, developed with GSK, showed positive results in two Phase 3 studies presented at EASL Congress 2026.

May 28 Ionis

Ionis partner GSK reports bepirovirsen functional cure results

Bepirovirsen met primary endpoint with 19% functional cure vs 0% placebo, and 26% in patients with lower HBsAg levels.

Media coverage

June 17 Investing.com

Ionis Pharmaceuticals director sells $587,920 in stock By Investing.com

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may...

June 13 The Globe and Mail

Ionis Highlights Positive Long-Term Olezarsen Data in Hypertriglyceridemia

Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

June 8 BioXconomy

Ionis’ ASO for neurological disorder awaits FDA’s decision

The new therapy for Alexander disease awaits approval after its clinical trial missed secondary endpoints.

June 5 TradingView

Key facts: Ionis licenses salanersen to Biogen; sees >$7B peak — TradingView News

Ionis Pharmaceuticals expects >$7B peak annual revenue and positive cash flow by 2028, driven by late-stage cardiometabolic and neurology programs, multiple planned launches, and its...

Never miss news about Ionis

Track Ionis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Ionis competitors & trending companies

Browse news for competitors to Ionis and other trending companies.